Evidence map›Paper›PMID 42842305›Full record

ArticleThe Journal of general virology2026

Sensitive reverse transcription-digital droplet PCR-based discrimination of hepatitis delta virus RNAs reveals differential effects of interferon-α on viral RNA species.

Caroline Pons, Emilie Charles, Cassandre Authier, Elise Chabot, Roxanne Fouillé, Faustine Bernardin, Claudie Eber, Léa Corbet, Maud Michelet, Marine Oudot and 10 more

Abstract read
In one paragraph

Article in The Journal of general virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Caroline PonsCIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111,, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.
Emilie CharlesCIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111,, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.
Cassandre AuthierCIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111,, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.
Elise ChabotCIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111,, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.
Roxanne FouilléCIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111,, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.
Faustine BernardinCIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111,, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.
Claudie EberInstitute for Translational Medicine and Liver Disease, Université de Strasbourg, Inserm, UMRS 1110, Strasbourg, France.
Léa CorbetCIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111,, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.
Maud MicheletINSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard, Lyon, France.
Marine OudotInstitute for Translational Medicine and Liver Disease, Université de Strasbourg, Inserm, UMRS 1110, Strasbourg, France.
Charlotte BachInstitute for Translational Medicine and Liver Disease, Université de Strasbourg, Inserm, UMRS 1110, Strasbourg, France.
Michel RivoireCentre Léon Bérard (CLB), INSERM, U1032, Lyon, France.
Guillaume PassotService de chirurgie générale et oncologique, Hôpital Lyon Sud, Hospices Civils de Lyon Et CICLY, EA3738, Université Lyon 1, Lyon, France.
Thomas F BaumertInstitute for Translational Medicine and Liver Disease, Université de Strasbourg, Inserm, UMRS 1110, Strasbourg, France.
Karim MajzoubInstitut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier, CNRS UMR5535, Montpellier, France.
Eric HuntzingerIGBMC, Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS UMR 7104, Inserm U 1258, Université de Strasbourg, Illkirch, France.
Bertrand SeraphinIGBMC, Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS UMR 7104, Inserm U 1258, Université de Strasbourg, Illkirch, France.
David DurantelCIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111,, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.
Eloi R VerrierCIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111,, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.
Julie LuciforaCIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111,, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis delta virus (HDV) replication relies on the production of distinct viral RNA species, including genomic (HDV-G), antigenomic (HDV-AG) and mRNAs (HDV mRNAs), which differ in abundance and function. However, the lack of sensitive and quantitative approaches allowing their simultaneous discrimination has limited the precise analysis of HDV RNA dynamics, particularly under antiviral conditions. Here, we combined nascent RNA and RNA stability assays with a novel reverse transcription digital droplet PCR (RT-ddPCR) approach enabling strand-specific quantification of HDV RNAs. Using this methodology, we confirmed the previously described kinetics of viral RNA production and assessed the ratio of each RNA species in HDV-infected cells. Specific small interfering RNA (siRNA) treatment demonstrated the specificity of our assay in discriminating HDV RNA species. Next, applying this technique to the study of virus-host interactions, we showed that IFN-α treatment decreases the synthesis of HDV-G and may additionally accelerate HDV-AG and HDV-G decay, while HDV mRNA stability remained unaffected in infected HuH7.5-Na+-taurocholate cotransporting polypeptide (NTCP) cells. Immunoprecipitation assays coupled to strand-specific RT-ddPCR revealed no difference in the association of cellular RNA polymerase II (Pol II) with HDV-G and HDV-AG. In parallel, transcriptomic analyses of differentiated HepaRG and HuH7.5-NTCP cells following IFN-α treatment identified IFN-stimulated gene candidates with potential anti-HDV activity. Among them, we showed that HELZ2 overexpression does not affect HDV RNA stability but interferes with HDV-AG and HDV-G RNA synthesis. Altogether, this RT-ddPCR-based approach provides a versatile tool to investigate the effects of current and emerging antiviral strategies on individual HDV RNA species.

Indexed as

Hepatitis Delta VirusInterferon-alphaReverse Transcriptase Polymerase Chain ReactionRNA, ViralAntiviral AgentsCell LineHepatitis DHumansRNA ReplicationRNA StabilityVirus ReplicationAntiviral AgentsInterferon-alphaRNA, Viralantiviralshepatitis delta virus (HDV)interferon (IFN)interferon-stimulated gene (ISG)reverse transcription digital droplet PCR (RT-ddPCR)

Identifiers

PMID42842305
PMCPMC13644934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.